Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Shares of Genmab A/S Sponsored ADR (GMAB) have gained 3.8% over the past four weeks to close the last trading session at ...

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

Genmab's (GMAB) stock gains as its lymphoma drug epcoritamab developed with AbbVie (ABBV) succeeds in a Phase 3 lymphoma ...

Danish biotech Genmab (Nasdaq: GMAB) posted second-quarter revenue of $925 million, up 19% from a year earlier, driven by ...

Genmab A/S (NASDAQ:GMAB) develops antibody therapeutics for the treatment of cancer and other diseases. H.C. Wainwright analyst Ram Selvaraju reiterated a “Buy” rating on the company’s ...

Looking at the chart above, GMAB's low point in its 52 week range is $25.38 per share, with $42.70 as the 52 week high point — that compares with a last trade of $25.81.

GMAB is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that GMAB is likely the superior ...